MedTechReport_Muster

11 Ceballos-Baumann A.  Subkutane Apomorphin-Dauerinfusion – Expertenkonsens Thieme MedTech Report Schwerpunkt 13 Krack P, et al. Five-year follow-up of bilateral sti- mulation of the subthalamic nucleus in advan- ced Parkinson‘s disease. N Engl J Med. 2003; 349: 1925–1934 14 Schupbach WM, et al. Stimulation of the subthala- mic nucleus in Parkinson‘s disease: a 5 year follow up. J Neurol Neurosurg Psychiatry 2005; 76: 1640– 1644 15 Merola A, et al. Parkinson‘s disease progression at 30 years: a study of subthalamic deep brain-stimu- lated patients. Brain 2011; 134: 2074–2084 16 Voges J, et al. Thirty days complication rate fol- lowing surgery performed for deep-brain-stimula- tion. Mov Disord 2007; 22: 1486–1489 17 Factor SA, et al. Subcutaneous apomorphine in- jections as a treatment for intractable pain in Parkinson‘s disease. Mov Disord 2000; 15: 167–169 18 Reuter I, et al. Nocturnal subcutaneous apomor- phine infusion in Parkinson‘s disease and restless legs syndrome. Acta Neurol Scand 1999; 100: 163– 167 19 Bailbe M, et al. Amélioration des troubles de la dé- glutition par l‘apomorphine en perfusion sous cuta- née au décours de la mise en place d‘électrodes de stimulation cérébrale profonde, dans la maladie de Parkinson. Rev Neurol (Paris) 2004; 160: 352–353 20 Kempster PA, et al. Off-period belching due to a reversible disturbance of oesophageal motility in Parkinson‘s disease and its treatment with apo- morphine. Mov Disord 1989; 4: 47–52 21 Tison F, et al. Effects of central dopaminergic sti- mulation by apomorphine on swallowing disorders in Parkinson‘s disease. Mov Disord 1996; 11: 729– 732 22 Christmas TJ, et al. Role of subcutaneous apomor- phine in parkinsonian voiding dysfunction. Lancet 1988; 2: 1451–1453 23 Edwards LL, et al. Defecatory function in Parkinson‘s disease: response to apomorphine. Ann Neurol 1993; 33: 490–493 24 Di Rosa AE, et al. Continuous apomorphine infu- sion and neuropsychiatric disorders: a controlled study in patients with advanced Parkinson‘s dis­ ease. Neurol Sci 2003; 24: 174–175 25 Deleu D, et al. Subcutaneous apomorphine: an vidence-based review of its use in Parkinson‘s dis­ ease. Drugs Aging 2004; 21: 687–709 26 García Ruiz PJ, et al. Efficacy of long-term con- tinuous subcutaneous apomorphine infusion in advanced Parkinson‘s disease with motor fluctua- tions: a multicenter study. Mov Disord 2008; 23: 1130–1136 27 Acland KM, et al. Panniculitis in association with apomorphine infusion. Br J Dermatol 1998; 138: 480–482 28 van Laar T, et al. The role of EDTA in provoking aller­gic reactions to subcutaneous infusion of apo- morphine in patients with Parkinson‘s disease: a histologic study. Mov Disord 1998; 13: 52–55 29 Marion MH, et al. How to avoid skin nodules with subcutaneous apomorphine infusion. MDS 13th Inter­national Congress. Paris, 7.–11.6.2009 30 Coelho M, et al. Late-stage Parkinson‘s disease: the Barcelona and Lisbon cohort. J Neurol 2010; 257: 1524–1532 31 Manor Y, et al. Validation of a swallowing distur- bance questionnaire for detecting dysphagia in pa- tients with Parkinson‘s disease. Mov Disord 2007; 22: 1917–1921 32 Fuh JL, et al. Swallowing difficulty in Parkinson‘s disease. Clin Neurol Neurosurg 1997; 99: 106–112 33 Baijens LW, et al. Effects of therapy for dysphagia in Parkinson‘s disease: systematic review. Dysphagia 2009; 24: 91–102 34 Deane KH, et al. Speech and language therapy for dysarthria in Parkinson‘s disease. Cochrane Data- base Syst Rev 2001;(2):CD002812 35 El Sharkawi A, et al. Swallowing and voice effects of Lee Silverman Voice Treatment (LSVT): a pilot stu- dy. J Neurol Neurosurg Psychiatry 2002; 72: 31–36 36 Troche MS, et al. Aspiration and swallowing in Par- kinson disease and rehabilitation with EMST: a ran- domized trial. Neurology 2010; 75: 1912–1919 37 Bushmann M, et al. Swallowing abnormalities and their response to treatment in Parkinson‘s disease. Neurology 1989; 39: 1309–1314 38 Robertson LT, Hammerstad JP. Jaw movement dys- function related to Parkinson‘s disease and par­ tially modified by levodopa. J Neurol Neurosurg Psychiatry 1996; 60: 41–50 39 Hunter PC, et al. Response of parkinsonian swal- lowing dysfunction to dopaminergic stimulation. J Neurol Neurosurg Psychiatry 1997; 63: 579–583 40 Suttrup I, et al. Dysphagia 2011; 26: 482 41 Monte FS, et al. Swallowing abnormalities and dys- kinesia in Parkinson‘s disease. Mov Disord 2005; 20: 457–462 42 Warnecke T, et al. Endoscopic characteristics and levodopa responsiveness of swallowing function in progressive supranuclear palsy. Mov Disord 2010; 25: 1239–1245 43 Ehret R, et al. Direkte Kosten der Parkinson- Behandlung. Eine Erhebung in neurologischen Schwerpunktpraxen in Berlin. Nervenarzt 2009; 80: 452–458 44 von Campenhausen S, et al. Costs of illness and care in Parkinson‘s disease: an evaluation in six countries. Eur Neuropsychopharmacol 2011; 21: 180–191 45 Dengler I, et al. Prospektive Erfassung der direkten und indirekten Kosten des idiopathischen Parkin- son-Syndroms. Nervenarzt 2006; 77: 1204–1209 46 Parkinson-Syndrome: Diagnostik und Therapie. Leitlinien der Deutschen Gesellschaft für Neuro­ logie, aus: H. C. Diener, N. Putzki: „Leitlinien für die Diagnostik und Therapie in der Neurologie“, Georg Thieme Verlag, 4. überarb. Auflage 2008 47 Die Parkinson-Krankheit – Grundlagen, Klinik, The- rapie. Gerlach M, Reichmann H, Riederer P (Hrsg.). Springer Wien New York, 2007

Seitenübersicht